Rigel Pharmaceuticals is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following press release that they conduct pre-clinical trials of their drugs on animals.
“R406 has been shown effective in preliminary animal models of arthritis and appears to be well tolerated in preclinical studies.” Read the following article
Rigel Pharmaceuticals, Inc. is a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The company focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Its current product development programs include Fostamatinib Oral SYK Inhibitor and R348 Topical Ophthalmic JAK/SYK Inhibitor.
Company Website: http://www.rigel.com